Bevacizumab Monotherapy for Metastatic Renal Cell Carcinoma in a Pediatric Patient

Hadelle Habitzreuter Hassmann, Ana Paula Kuczynski Pedro Bom and Lucas Henrique de Almeida Silva

Department of Pediatric Oncology, Little Prince Hospital, Brazil

^*Correspondance to: [email protected] 

 PDF  Full Text Case Report | Open Access

Abstract:

Renal cell carcinoma rarely occurs in children and adolescents. Localized disease has good prognosis, whereas distant metastasis have poor prognosis, with no effective therapy. Recently, 10% to 20% of adult patients have shown an apparent response to immunotherapy; however the limited pediatric experience confirms a very poor prognosis. We present a case from a patient with renal cell carcinoma with liver metastasis who has been treating with bevacizumab for ten years. She is doing well, without side effects, presenting reduction in size and number of the liver nodules.

Keywords:

Cite the Article:

Hassmann HH, Pedro Bom APK, de Almeida Silva LH. Bevacizumab Monotherapy for Metastatic Renal Cell Carcinoma in a Pediatric Patient. Clin Oncol. 2022;7:1888..